JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online July 13, 2007, 10.2967/jnumed.107.041301
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagengast, W. B.
Right arrow Articles by Lub-de Hooge, M. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagengast, W. B.
Right arrow Articles by Lub-de Hooge, M. N.

In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft

Wouter B. Nagengast1, Elisabeth G. de Vries1, Geke A. Hospers1, Nanno H. Mulder1, Johan R. de Jong2, Harry Hollema3, Adrienne H. Brouwers2, Guus A. van Dongen4, Lars R. Perk4 and Marjolijn N. Lub-de Hooge2,5

1 Department of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands; 2 Department of Nuclear Medicine and Molecular Imaging, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands; 3 Department of Pathology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands; 4 Department of Nuclear Medicine and PET Research, VU Medical Center, Amsterdam, The Netherlands; and 5 Department of Hospital and Clinical Pharmacy, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands


Figure 1
View larger version (26K):
[in this window]
[in a new window]

  		FIGURE 1.  Coronal CT image (A) with clear subcutaneous localization of SKOV-3 tumor (arrow). Fusion of microPET and CT images (B) (168 h after injection) enables adequate quantitative measurement of 89Zr-bevacizumab in the tumor.

 

Figure 2
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 2.  Coronal planes of microPET images 24 h (A), 72 h (B), and 168 h (C) after injection of 89Zr-bevacizumab. At 24 h, most uptake is in well-perfused organs. In time, relative uptake in the tumor (arrow) increases.

 

Figure 3
View larger version (7K):
[in this window]
[in a new window]

  		FIGURE 3.  Comparison of tumor uptake of 89Zr-bevacizumab and control 89Zr-IgG as determined by noninvasive microPET imaging ({blacksquare}) (n = 6) and by {gamma}-counting of excised tumors ({square}) (n = 6) 168 h after injection. Data are presented as %ID/g ± SD, assuming a tissue density of 1 g/cm3.

 

Figure 4
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 4.  Ex vivo biodistribution of 89Zr-bevacizumab (n = 6) ({blacksquare}) and control 89Zr-IgG (n = 6) ({square}) 168 h after injection. Uptake of 89Zr-bevacizumab within the tumor is significantly higher than that of control 89Zr-IgG (P = 0.006). Data are presented as %ID/g ± SD. *P ≤ 0.05.

 

Figure 5
View larger version (120K):
[in this window]
[in a new window]

  		FIGURE 5.  Antihuman IgG staining (arrow) in a tumor slice from mice receiving 89Zr-bevacizumab.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.